JP2020015679A - 下部尿路症状改善用組成物 - Google Patents
下部尿路症状改善用組成物 Download PDFInfo
- Publication number
- JP2020015679A JP2020015679A JP2018139168A JP2018139168A JP2020015679A JP 2020015679 A JP2020015679 A JP 2020015679A JP 2018139168 A JP2018139168 A JP 2018139168A JP 2018139168 A JP2018139168 A JP 2018139168A JP 2020015679 A JP2020015679 A JP 2020015679A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- urinary tract
- symptoms
- polymethoxyflavonoid
- lower urinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 206010071289 Lower urinary tract symptoms Diseases 0.000 title claims abstract description 73
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 69
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 44
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 claims abstract description 44
- 241000207199 Citrus Species 0.000 claims abstract description 40
- 239000004471 Glycine Substances 0.000 claims abstract description 34
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 claims abstract description 22
- IECRXMSGDFIOEY-UHFFFAOYSA-N Tangeretin Natural products COC=1C(OC)=C(OC)C(OC)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 IECRXMSGDFIOEY-UHFFFAOYSA-N 0.000 claims abstract description 22
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 claims abstract description 22
- LKMNXYDUQXAUCZ-UHFFFAOYSA-N sinensetin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C=C2O1 LKMNXYDUQXAUCZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- QEWSAPKRFOFQIU-UHFFFAOYSA-N 5-Hydroxy-6,7,3',4'-tetramethoxyflavone Natural products C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C=C2O1 QEWSAPKRFOFQIU-UHFFFAOYSA-N 0.000 claims abstract description 7
- AAASNKNLMQBKFV-UHFFFAOYSA-N quercetin 5,7,3',4'-tetramethyl ether Chemical compound C=1C(OC)=CC(OC)=C(C(C=2O)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 AAASNKNLMQBKFV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims description 42
- 230000002485 urinary effect Effects 0.000 claims description 36
- 235000013305 food Nutrition 0.000 claims description 25
- 210000002700 urine Anatomy 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 15
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 15
- 208000020629 overactive bladder Diseases 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000006872 improvement Effects 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 3
- 229930003935 flavonoid Natural products 0.000 abstract 3
- 150000002215 flavonoids Chemical class 0.000 abstract 3
- 235000017173 flavonoids Nutrition 0.000 abstract 3
- 230000027939 micturition Effects 0.000 description 43
- 230000000694 effects Effects 0.000 description 35
- 239000002775 capsule Substances 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 210000003932 urinary bladder Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 241001672694 Citrus reticulata Species 0.000 description 12
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 9
- 206010046555 Urinary retention Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010036018 Pollakiuria Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 206010029446 nocturia Diseases 0.000 description 7
- 230000036318 urination frequency Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 206010013990 dysuria Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 210000003708 urethra Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000022934 urinary frequency Diseases 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 240000002319 Citrus sinensis Species 0.000 description 3
- 235000005976 Citrus sinensis Nutrition 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 201000004240 prostatic hypertrophy Diseases 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000000143 urethritis Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 241000548268 Citrus deliciosa Species 0.000 description 2
- 241000054078 Citrus depressa Species 0.000 description 2
- 241000951471 Citrus junos Species 0.000 description 2
- 241000675110 Citrus sunki Species 0.000 description 2
- 241000555678 Citrus unshiu Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027566 Micturition urgency Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000010829 Spina bifida Diseases 0.000 description 2
- 208000006097 Spinal Dysraphism Diseases 0.000 description 2
- 208000028994 Spinal vascular disease Diseases 0.000 description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000028484 Urethral disease Diseases 0.000 description 2
- 206010065584 Urethral stenosis Diseases 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- 208000028938 Urination disease Diseases 0.000 description 2
- 206010072731 White matter lesion Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 206010005038 bladder diverticulum Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- -1 chlormadinone Chemical compound 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001551 mirabegron Drugs 0.000 description 2
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 208000026455 prostate symptom Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019685 rice crackers Nutrition 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000022170 stress incontinence Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000001988 urethral stricture Diseases 0.000 description 2
- 206010046494 urge incontinence Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241000679029 Citrus kinokuni Species 0.000 description 1
- 241000675268 Citrus leiocarpa Species 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241001140724 Citrus tachibana Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 244000295848 Citrus x nobilis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011796 Cystitis interstitial Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013530 Diverticula Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000510678 Falcaria vulgaris Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010058914 Hypotonic urinary bladder Diseases 0.000 description 1
- 241000450082 Joppa Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 241000694486 Stewartia <clam> Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 206010062225 Urinary tract pain Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000020054 awamori Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000010585 urethral diverticulum Diseases 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
[1]ポリメトキシフラボノイドと、グリシンとを有効成分として含有する、下部尿路症状改善用組成物。
[2]柑橘類のポリメトキシフラボノイド含有物と、グリシンとを有効成分として含有する、下部尿路症状改善用組成物。
[3]前記ポリメトキシフラボノイドは、ノビレチン、タンゲレチン、3’,4’,5,7−テトラメチルケルセチン及びシネンセチンからなる群から選ばれる少なくとも1種のポリメトキシフラボノイドである、[1]〜[2]のいずれか1項に記載の組成物。
[4]前記組成物は、畜尿症状、排尿症状及び排尿後症状からなる群より選ばれる少なくとも1種の下部尿路症状を改善するための組成物である、[1]〜[3]のいずれか1項に記載の組成物。
[5]前記組成物は、飲食品又は医薬品の形態にある下部尿路症状改善用組成物である、[1]〜[4]のいずれか1項に記載の組成物。
[6]前記組成物は、有効成分の投与量が、下記(1)〜(3)の少なくとも1種の投与量である、[1]〜[5]のいずれか1項に記載の組成物。
(1)成人1日あたりのノビレチンの投与量が30mg以上である
(2)成人1日あたりのタンゲレチンの投与量が15mg以上である
(3)成人1日あたりのグリシンの投与量が3g以上である
[7][1]〜[6]のいずれか1項に記載の組成物を、個体に投与することにより、該個体の下部尿路症状を改善する工程を含む、下部尿路症状の改善方法。
R1は水素又は水酸基であり;R2〜R10はそれぞれ独立して水素、−OH又は−OCH3であり、ただし、R2〜R10のうち3個以上は−OCH3である。)
で示される化合物である。
(1−1.目的)
排尿障害のある成人ボランティアに対する、ノビレチン及びタンゲレチン含有物並びにグリシンを含有する製剤の排尿障害改善作用について評価した。
賦形剤としてデキストリンを用いて、ノビレチン及びタンゲレチン含有物 50mgと、グリシン 3gとを含有するカプセル剤を実施例1のカプセル剤とし、ノビレチン及びタンゲレチン含有物 50mgのみを含有するカプセル剤を比較例1のカプセル剤とした。
42例のうち、25例(男7例、女18例、年齢48±14歳)を実施例1のカプセル剤を経口的に服用する実施例群とし、残りの17例(男13例、女4例、年齢65±13歳)を比較例1のカプセル剤を経口的に服用する比較例群とした。
カプセル剤は、1日1回朝、連日的に服用(内服)した。カプセル剤の服用前(0日)、カプセル剤服用3週間後及びカプセル剤服用6週間後に、各対象例について、排尿関連症状としての日中排尿回数(実数)、夜間排尿回数(実数)、過活動膀胱症状スコア(OABSS)、国際前立腺症状スコア(IPSS)及びIPSS−QOLスコアを測定した。このうち、OABSS、IPSS及びIPSS−QOLについては、日本泌尿器科学会編、「男性下部尿路症状・前立腺肥大症診療ガイドライン」(2017年4月20日 発行)を参照して測定した。
実施例群及び比較例群の結果をそれぞれ図1及び図2に示す。なお、両群ともに、副作用などの有害事象は認められなかった。
Claims (6)
- ポリメトキシフラボノイドと、グリシンとを有効成分として含有する、下部尿路症状改善用組成物。
- 柑橘類のポリメトキシフラボノイド含有物と、グリシンとを有効成分として含有する、下部尿路症状改善用組成物。
- 前記ポリメトキシフラボノイドは、ノビレチン、タンゲレチン、3’,4’,5,7−テトラメチルケルセチン及びシネンセチンからなる群から選ばれる少なくとも1種のポリメトキシフラボノイドである、請求項1〜2のいずれか1項に記載の組成物。
- 前記組成物は、畜尿症状、排尿症状、排尿後症状及び過活動膀胱からなる群より選ばれる少なくとも1種の下部尿路症状を改善するための組成物である、請求項1〜3のいずれか1項に記載の組成物。
- 前記組成物は、飲食品又は医薬品の形態にある下部尿路症状改善用組成物である、請求項1〜4のいずれか1項に記載の組成物。
- 前記組成物は、有効成分の投与量が、下記(1)〜(3)の少なくとも1種の投与量である、請求項1〜5のいずれか1項に記載の組成物。
(1)成人1日あたりのノビレチンの投与量が30mg以上である
(2)成人1日あたりのタンゲレチンの投与量が15mg以上である
(3)成人1日あたりのグリシンの投与量が3g以上である
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018139168A JP7219907B2 (ja) | 2018-07-25 | 2018-07-25 | 下部尿路症状改善用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018139168A JP7219907B2 (ja) | 2018-07-25 | 2018-07-25 | 下部尿路症状改善用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020015679A true JP2020015679A (ja) | 2020-01-30 |
JP7219907B2 JP7219907B2 (ja) | 2023-02-09 |
Family
ID=69580022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018139168A Active JP7219907B2 (ja) | 2018-07-25 | 2018-07-25 | 下部尿路症状改善用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7219907B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020262689A1 (ja) | 2019-06-28 | 2020-12-30 | 富士フイルム株式会社 | 機上現像型平版印刷版原版、平版印刷版の作製方法、及び、平版印刷方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522391A (ja) * | 1998-08-03 | 2002-07-23 | イー ホウィーラー,ロナルド | 前立腺配合物 |
JP2003128566A (ja) * | 2001-08-09 | 2003-05-08 | Maruzen Pharmaceut Co Ltd | 膀胱機能改善剤又は排尿障害治療剤、及び膀胱機能改善用又は排尿障害治療用飲食物 |
JP2004091366A (ja) * | 2002-08-30 | 2004-03-25 | Rohto Pharmaceut Co Ltd | ノコギリヤシ抽出物組成物およびその用途 |
JP2005206546A (ja) * | 2004-01-23 | 2005-08-04 | Maruzen Pharmaceut Co Ltd | アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤 |
JP2013035833A (ja) * | 2011-07-13 | 2013-02-21 | Daiichi Sankyo Healthcare Co Ltd | 頻尿治療用組成物 |
WO2016075960A1 (ja) * | 2014-11-12 | 2016-05-19 | 株式会社沖縄リサーチセンター | 排尿障害を予防又は改善させる医薬組成物、排尿障害関連受容体に関する拮抗剤又はその医薬組成物又は拮抗剤を用いた排尿障害を予防又は改善させる方法 |
JP2016539183A (ja) * | 2013-11-11 | 2016-12-15 | ナチュレックス−ディービーエス エルエルシー | 下部尿路症状、良性前立腺過形成、勃起障害の治療に有用な組成物及び方法 |
-
2018
- 2018-07-25 JP JP2018139168A patent/JP7219907B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002522391A (ja) * | 1998-08-03 | 2002-07-23 | イー ホウィーラー,ロナルド | 前立腺配合物 |
JP2003128566A (ja) * | 2001-08-09 | 2003-05-08 | Maruzen Pharmaceut Co Ltd | 膀胱機能改善剤又は排尿障害治療剤、及び膀胱機能改善用又は排尿障害治療用飲食物 |
JP2004091366A (ja) * | 2002-08-30 | 2004-03-25 | Rohto Pharmaceut Co Ltd | ノコギリヤシ抽出物組成物およびその用途 |
JP2005206546A (ja) * | 2004-01-23 | 2005-08-04 | Maruzen Pharmaceut Co Ltd | アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤 |
JP2013035833A (ja) * | 2011-07-13 | 2013-02-21 | Daiichi Sankyo Healthcare Co Ltd | 頻尿治療用組成物 |
JP2016539183A (ja) * | 2013-11-11 | 2016-12-15 | ナチュレックス−ディービーエス エルエルシー | 下部尿路症状、良性前立腺過形成、勃起障害の治療に有用な組成物及び方法 |
WO2016075960A1 (ja) * | 2014-11-12 | 2016-05-19 | 株式会社沖縄リサーチセンター | 排尿障害を予防又は改善させる医薬組成物、排尿障害関連受容体に関する拮抗剤又はその医薬組成物又は拮抗剤を用いた排尿障害を予防又は改善させる方法 |
Non-Patent Citations (1)
Title |
---|
THE JOURNAL OF UROLOGY, vol. 173, JPN6022030118, 2005, pages 314 - 317, ISSN: 0004946936 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020262689A1 (ja) | 2019-06-28 | 2020-12-30 | 富士フイルム株式会社 | 機上現像型平版印刷版原版、平版印刷版の作製方法、及び、平版印刷方法 |
Also Published As
Publication number | Publication date |
---|---|
JP7219907B2 (ja) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009502958A (ja) | ストレスの治療または管理の方法 | |
US10709754B2 (en) | Composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising extract of Alpinia oxyphylla as effective ingredient | |
US20200268827A1 (en) | Composition for prevention, improvement or treatment of osteoarthritis comprising alpinia oxyphylla extract as effective component | |
EP1618875A1 (en) | Composition for inhibition or prevention of bone density lowering and refreshment therefor | |
JP5940347B2 (ja) | 過活動膀胱の予防又は改善剤 | |
JP6545185B2 (ja) | インドナガコショウ抽出物を含む排尿障害の予防、治療及び改善用組成物 | |
KR102204346B1 (ko) | 갱년기 증상 또는 골다공증 개선용 조성물 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
CN107624068B (zh) | 包含肉桂醛和锌的组合物及此类组合物的使用方法 | |
JP7219907B2 (ja) | 下部尿路症状改善用組成物 | |
CN106028837B (zh) | 使用肉桂醛和锌进行体重管理的方法和组合物 | |
KR101142759B1 (ko) | 염증성 장 질환 개선제 조성물 | |
JP2017209108A (ja) | 更年期症状又は骨粗鬆症改善用組成物 | |
JP7444375B2 (ja) | 下部尿路症状改善用組成物 | |
KR102536959B1 (ko) | 내복자 추출물을 포함하는 악액질의 예방, 개선 또는 치료용 조성물 | |
KR101659667B1 (ko) | 맥아 추출물을 함유하는 성장 장애 예방 또는 치료용 조성물 | |
TWI784169B (zh) | 夜間頻尿之預防或改善劑 | |
WO2021112263A1 (ja) | アディポネクチン産生促進剤 | |
JP2004244389A (ja) | 栄養補助食品 | |
KR101867457B1 (ko) | 살리드로사이드 및 베툴린을 유효성분으로 포함하는 유방암 예방 또는 치료를 위한 조성물 | |
WO2019009354A1 (ja) | 排尿障害改善用組成物 | |
KR20170036883A (ko) | 복합 추출물을 포함하는 배뇨 장애 예방, 치료 및 개선용 조성물 | |
KR20110124744A (ko) | 염증성 장 질환 개선제 조성물 | |
WO2021173166A1 (en) | Compositions and methods for treating urinary conditions | |
KR20230054121A (ko) | 남성 갱년기 증후군 예방 및 개선용 조성물 및 이를 포함한 식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210721 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7219907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |